Namely, SMOC1, ALDOA, MAP1B and YWHAZ proteins emerged as biomarker candidates with low coefficients of variation that could best discriminate AD from non-AD cases with cognitive impairment as well as predict individuals with high Tau/Aβ ratio in CSF. Here, ALDOA is linked to Cognitive impairment.